These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30582385)

  • 1. Actinic keratosis and imiquimod: a review of novel carriers and patents.
    Sharma M; Sharma G; Singh B; Katare OP
    Expert Opin Drug Deliv; 2019 Feb; 16(2):101-112. PubMed ID: 30582385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.
    Befon A; Tzanetakou V; Panagiotopoulos A; Chasapi V; Antoniou C; Stratigos AJ
    Int J Dermatol; 2019 Sep; 58(9):1040-1044. PubMed ID: 30779341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
    Rowlands MA; Giacometti JN; Servat J; Materin MA; Levin F
    Ophthalmic Plast Reconstr Surg; 2017; 33(1):e21-e23. PubMed ID: 25853505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
    Strohal R; Kerl H; Schuster L
    J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
    Quist SR; Gollnick HP
    Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod.
    Ogawa Y; Kawamura T; Matsuzawa T; Aoki R; Shimada S
    J Dermatol Sci; 2014 Oct; 76(1):67-9. PubMed ID: 25088809
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
    Tambone S; Fargnoli MC; Capizzi R; Peris K
    G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
    Neugebauer R; Su KA; Zhu Z; Sokil M; Chren MM; Friedman GD; Asgari MM
    J Am Acad Dermatol; 2019 Apr; 80(4):998-1005. PubMed ID: 30458208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate.
    Serra-Guillen C; Nagore E; Hueso L; Llombart B; Requena C; Sanmartín O; Botella-Estrada R; Guillen C
    Br J Dermatol; 2011 Feb; 164(2):429-33. PubMed ID: 20973770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
    Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
    J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
    Yu A; Tanizaki H; Kokunai Y; Kaneda K; Sugimoto A; Otsuka T; Kurokawa T; Moriwaki S
    J Dermatol; 2018 Apr; 45(4):496-500. PubMed ID: 29265412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-Day Course of Imiquimod 5% for the Treatment of Actinic Keratosis: Effectiveness and Local Reactions.
    Serra-Guillén C; Nagore E; Llombart B; Sanmartín O; Requena C; Calomarde L; Guillén C
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):248-253. PubMed ID: 29246367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation and efficacy of Imiquimod 3.75% cream for the treatment of actinic keratosis, pigmented basal cell carcinomas, and actinic cheilitis.
    Paolino G; Cantoresi F; Mercuri SR; Cantisani C
    Dermatol Ther; 2020 May; 33(3):e13356. PubMed ID: 32239714
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
    Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
    J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
    Tanaka N; Ohata C; Ishii N; Imamura K; Ueda A; Furumura M; Yasumoto S; Kawakami T; Tsuruta D; Hashimoto T
    J Dermatol; 2013 Dec; 40(12):962-7. PubMed ID: 24147543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod cream in the treatment of actinic keratoses.
    Persaud A; Lebwohl M
    J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S236-9. PubMed ID: 12271285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the back of the hands to apply imiquimod.
    Hogan K; Cullan J; Isedeh P; Aires D
    J Am Acad Dermatol; 2016 Jan; 74(1):e17. PubMed ID: 26702809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.